RTT Press Release
|03/06/2017 - 22:23||
Arthritis Limits Daily Activities of 24 million US Adults
Arthritis will increase as the population grows and ages.
|03/06/2017 - 21:14||
Study in the American Journal of Obstetrics & Gynecology finds Maternal Safety Toolkits and Health Care Collaboration Reduced the Most Common Cause of Maternal Death Worldwide
WASHINGTON (March 6, 2017)— In a study in the American Journal of Obstetrics & Gynecology researchers with the California Maternal Quality Care Collaborative, based at Stanford University, Palo Alto, California, found that using a series of maternal safety toolkits and collaborating across multiple professional health care organizations could effectively reduce obstetric hemorrhage—the most common cause of maternal death worldwide. The study, Reduction of Severe Maternal Morbidity from Hemorrhage (SMM-HEM) Using a State-Wide Perinatal Collaborative was presented in January at the Society for Maternal-Fetal Medicine’s annual meeting, The Pregnancy Meeting™.
|Society for Mat...|
|03/06/2017 - 15:36||
Division of Public Health Using Technology to Help Physicians Fight Heart Disease And Lower Blood Pressure Among Delawareans
DOVER – One in three Americans has high blood pressure, and 48 percent of those who have it do not have it under control. In fact, more than one-third of people with hypertension are unaware they even have the condition. In 2015, over 255,000 Delawareans age 18 or older, suffered from high blood pressure, one of the primary factors that lead people to develop heart disease.
|Delaware State ...|
|03/06/2017 - 14:05||
Isoflavones in food associated with reduced mortality for women with some breast cancers
BOSTON (March 6, 2017)—An epidemiological analysis of data from more than 6,000 American and Canadian women with breast cancer finds that post-diagnosis consumption of foods containing isoflavones—estrogen-like compounds primarily found in soy food—is associated with a 21 percent decrease in all-cause mortality. This decrease was seen only in women with hormone-receptor-negative tumors, and in women who were not treated with endocrine therapy such as tamoxifen.
|03/06/2017 - 12:28||
CEL-SCI GIVES UPDATE ON PARTIAL CLINICAL HOLD ON PHASE 3 HEAD AND NECK CANCER STUDY WITH MULTIKINE
Vienna, VA, March 6, 2017 -- CEL-SCI Corporation (NYSE MKT: CVM) announces that it has received the official minutes from its February 8, 2017 meeting with the U.S. Food and Drug Administration (FDA) in regards to the partial clinical hold placed on the Phase 3 head and neck cancer study with CEL-SCI's investigational drug Multikine* (Leukocyte Interleukin, Injection) on September 26, 2016.
|03/06/2017 - 12:09||
Brazils Illegal Treatment of Women in Prison
To enter the unsanitary, violent, and inhumane cells of Brazil’s prisons is to step into a cruel netherworld where neither Brazilian nor international law seem to apply. For nearly 37,000 women behind bars, there is added anguish.
|Human Rights Watch|
|03/06/2017 - 11:55||
Salford hospital wasting cash and putting lives at risk, while ignoring calls for specialist NHS role
Health campaigners have criticised Salford Royal NHS Foundation Trust for ignoring calls to invest in specialist care for over 3,000 people with muscular dystrophy.
|03/06/2017 - 11:42||
New Pitt Center Will Study Diseases Linked to Misshapen Proteins
PITTSBURGH—Through a comprehensive understanding of how to fix protein architecture when it goes awry, University of Pittsburgh researchers will be positioned to improve prognoses for millions of people with debilitating diseases.
|03/06/2017 - 10:38||
The Skin Cancer Foundation Response: Repeal of the Tanning Tax
The American Health Care Act, introduced in the House of Representatives on March 6, 2017, includes a provision to repeal the 10 percent tax on indoor tanning that was included in the 2010 Affordable Care Act.
|Skin Cancer Fou...|
|03/06/2017 - 09:34||
Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes
KENILWORTH, N.J. & NEW YORK--( )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc.
|03/06/2017 - 09:30||
Phase 3 EINSTEIN CHOICE evaluated the efficacy and safety of continued use of XARELTO
TITUSVILLE, NJ (March 6, 2017) – Janssen Pharmaceuticals, Inc.
|Johnson and Johnson|
|03/06/2017 - 07:31||
Cancer 'Hot Spots' in Florida may be Associated with Hazardous Waste Sites
Studies have shown that hazardous waste sites have the potential to adversely affect human health and disrupt ecological systems. Florida has the sixth highest number of hazardous waste sites, known as Superfund sites, in the United States. In 2016, the state was projected to have the second largest number of new cancer cases in the country.
|MU School of Me...|
|03/06/2017 - 06:50||
West Yorkshire hospital wasting cash and putting lives at risk, while ignoring calls for specialist NHS role
Health campaigners have criticised Bradford Teaching Hospitals NHS Foundation Trust for ignoring calls to invest in expert care for people with muscular dystrophy in West Yorkshire.
|03/06/2017 - 06:42||
Professional pest management no more effective than do-it-yourself allergen reduction in improving asthma symptoms
Malik Fox and Shareki Chaney participated in the study because they wanted to learn how to reduce mouse allergens in their home and improve Malik’s asthma symptoms.
|Johns Hopkins H...|
|03/06/2017 - 01:13||
Patients More Likely To Refuse Drug Therapy Than Psychotherapy For Mental Health
WASHINGTON — People seeking help for mental disorders are more likely to refuse or not complete the recommended treatment if it involves only psychotropic drugs, according to a review of research published by the American Psychological Association.
|03/05/2017 - 10:34||
Oral OTEZLA (Apremilast) Demonstrated Significant Improvement versus Placebo in Trial of Patients with Moderate Plaque Psoriasis Who Were Nave to Systemic and Biologic Therapy
a. The UNVEIL study evaluated the clinical efficacy and safety of oral OTEZLA 30 mg twice daily compared with placebo at week 16 in 221 patients with moderate plaque psoriasis [defined as a BSA involvement of 5-10 percent and a static Physician's Global Assessment (sPGA) of 3] who were naïve to systemic and biologic therapy. At baseline, more than 80 percent of patients enrolled in the trial had previously received topical therapy. The primary endpoint was the mean percentage change from baseline in the product of PGA and BSA (PGA×BSA) at week 16.
|03/04/2017 - 21:34||
CT Scans May Offer a Non-invasive Alternative to Diagnose Immunotherapy-induced Colitis
PHILADELPHIA — Computed Tomography (CT) scans are a reliable tool to establish a diagnosis of immune-related colitis, a potentially life-threatening adverse event in patients with advanced melanoma who receive the immune checkpoint inhibitor ipilimumab, and this non-invasive approach could provide a safer alternative to a colonoscopy and biopsy to confirm colitis, according to a study published in Cancer Immunology Research, a journal of the American Association for Cancer Research.
|03/03/2017 - 16:27||
Compliance Code of Business Conduct and Ethics Sunshine Act FAQ CA Declaration of Compliance Vermont Prescriber Information
While many people believe that all breast cancers are the same, triple-negative breast cancer (TNBC) can be more aggressive and harder to treat than other types. In recognition of Triple-negative Breast Cancer Awareness Day on March 3, Celgene is raising awareness of what makes this breast cancer different and why more research is needed.
|03/03/2017 - 14:58||
University Health Services Advises Prevention to Fight Flu
In an email message to the campus community on March 3, Dr. George Corey, executive director of University Health Services (UHS), urged everyone to practice prevention during ‘flu’ season.
|University of M...|
|03/03/2017 - 13:59||
FDA approves first treatment for frequent urination at night due to overproduction of urine
The U.S. Food and Drug Administration today approved Noctiva (desmopressin acetate) nasal spray for adults who awaken at least two times per night to urinate due to a condition known as nocturnal polyuria (overproduction of urine during the night). Noctiva is the first FDA-approved treatment for this condition.
|03/03/2017 - 12:47||
Ipas issues 2017 updates to clinical abortion recommendations
Ipas’s annual release of Clinical Updates in Reproductive Health continues to offer the most up-to-date, evidence-based clinical recommendations on comprehensive abortion care in English and Spanish (and French coming soon), with new topics and resources added for 2017. As an organization offering technical assistance to health systems, Ipas promotes evidence-based clinical practice and the right to high-quality health care for all people—and uses the Clinical Updates to further these priorities.
|03/03/2017 - 11:35||
Ten million lives saved by 1962 breakthrough, study says
Nearly 200 million cases of polio, measles, mumps, rubella, varicella, adenovirus, rabies and hepatitis A — and approximately 450,000 deaths from these diseases — were prevented in the U.S. alone between 1963 and 2015 by vaccination, researchers estimate.
|03/03/2017 - 11:04||
Johnson & Johnson Consumer Inc. Presents 21 Scientific Posters/Abstracts At The 2017 American Academy of Dermatology Annual Meeting
SKILLMAN, N.J., March 3, 2017 -- As a global leader in scientifically driven skincare, Johnson & Johnson Consumer Inc.
|Johnson and Johnson|
|03/02/2017 - 17:33||
Early periods associated with risk of gestational diabetes
The age at which girls start menstruating could flag a later risk of diabetes during pregnancy, according to a University of Queensland study.
|03/02/2017 - 15:44||
NICE recommends advanced bowel cancer drugs for use on the NHS
Today the National Institute for Health and Care Excellence (NICE) published their recommendation that the drugs cetuximab and panitumumab should be made available on the NHS for the treatment of previously untreated metastatic bowel cancer.
|Beating Bowel Cancer|